Loading…

Inhibition of skin 5α-reductase by oral contraceptive progestins in vitro

Androgenic disorders of female skin such as hirsutism, acne and alopecia are etiologically caused by androgen excess. Skin 5α-reductase activity is a major factor influencing the manifestation of endogenous androgen excess in women. Oral contraceptives have proven useful for the treatment of androge...

Full description

Saved in:
Bibliographic Details
Published in:Gynecological endocrinology 2000, Vol.14 (4), p.223-230
Main Authors: Rabe, T., Kowald, A., Ortmann, J., Rehberger-Schneider, S.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c431t-7d1ca11dde84b4e667eb47e9c1b653411368412482ee822884ddb4015e9f54f73
cites cdi_FETCH-LOGICAL-c431t-7d1ca11dde84b4e667eb47e9c1b653411368412482ee822884ddb4015e9f54f73
container_end_page 230
container_issue 4
container_start_page 223
container_title Gynecological endocrinology
container_volume 14
creator Rabe, T.
Kowald, A.
Ortmann, J.
Rehberger-Schneider, S.
description Androgenic disorders of female skin such as hirsutism, acne and alopecia are etiologically caused by androgen excess. Skin 5α-reductase activity is a major factor influencing the manifestation of endogenous androgen excess in women. Oral contraceptives have proven useful for the treatment of androgen disorders of the skin. The mechanisms of action by which oral contraceptives correct skin androgen levels may include inhibition of 5α-reductase and androgen receptor activity. We investigated the inhibitory effect of oral contraceptive progestins and ethinyl estradiol on skin 5α-reductase and their influence on androgen receptor activity and affinity, using three different in vitro assay systems. It was shown that norgestimate blocked 5α-reductase activity with an IC50 value of 10 μM, followed by levonorgestrel (IC50 52 μM), dienogest (IC50 55 μM), cyproterone acetate (IC50 87 μM) and gestodene (IC50 98 μM). To determine the full androgenic potential of the progestins, androgen receptor binding affinities and activation potentials were determined. The progestins norgestimate and dienogest in particular combined 5α-reductase inhibition with minimal androgenic potential. These data demonstrate that the progestins norgestimate and dienogest might help in the treatment of clinical hyperandrogeny in women.
doi_str_mv 10.3109/09513590009167685
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72407307</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72407307</sourcerecordid><originalsourceid>FETCH-LOGICAL-c431t-7d1ca11dde84b4e667eb47e9c1b653411368412482ee822884ddb4015e9f54f73</originalsourceid><addsrcrecordid>eNp9kM9O20AQh1cVqEnTPkAvyAfEzbDj_WcLLhWiJQiJC5yt9XrcLDi7YXdNlcfqi_BMdZRUCCHlNIf5vtFvfoR8B3rKgFZntBLAREUprUAqWYpPZApcsZwqKQ_IdLPPN8CEfInxkVJgXBWfyQSAKlFUdEpu5m5hG5usd5nvsvhkXSZe_-YB28EkHTFr1pkPus-Mdylog6tkXzBbBf8bY7IuZqPxYlPwX8lhp_uI33ZzRh5-Xt1fXue3d7_mlz9uc8MZpFy1YDRA22LJG45SKmy4wspAIwXjAEyWHApeFohlUZQlb9uGUxBYdYJ3is3IyfbumOF5GEPUSxsN9r126IdYq4JTxegGhC1ogo8xYFevgl3qsK6B1psC6w8Fjs7R7vjQLLF9M3aNjcDxDtDR6L4L2hkb3zgBsqTViF1sMes6H5b6jw99Wye97n3477B9Mc7f6QvUfVoYHbB-9ENwY797nvgHEp6dNw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72407307</pqid></control><display><type>article</type><title>Inhibition of skin 5α-reductase by oral contraceptive progestins in vitro</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Rabe, T. ; Kowald, A. ; Ortmann, J. ; Rehberger-Schneider, S.</creator><creatorcontrib>Rabe, T. ; Kowald, A. ; Ortmann, J. ; Rehberger-Schneider, S.</creatorcontrib><description>Androgenic disorders of female skin such as hirsutism, acne and alopecia are etiologically caused by androgen excess. Skin 5α-reductase activity is a major factor influencing the manifestation of endogenous androgen excess in women. Oral contraceptives have proven useful for the treatment of androgen disorders of the skin. The mechanisms of action by which oral contraceptives correct skin androgen levels may include inhibition of 5α-reductase and androgen receptor activity. We investigated the inhibitory effect of oral contraceptive progestins and ethinyl estradiol on skin 5α-reductase and their influence on androgen receptor activity and affinity, using three different in vitro assay systems. It was shown that norgestimate blocked 5α-reductase activity with an IC50 value of 10 μM, followed by levonorgestrel (IC50 52 μM), dienogest (IC50 55 μM), cyproterone acetate (IC50 87 μM) and gestodene (IC50 98 μM). To determine the full androgenic potential of the progestins, androgen receptor binding affinities and activation potentials were determined. The progestins norgestimate and dienogest in particular combined 5α-reductase inhibition with minimal androgenic potential. These data demonstrate that the progestins norgestimate and dienogest might help in the treatment of clinical hyperandrogeny in women.</description><identifier>ISSN: 0951-3590</identifier><identifier>EISSN: 1473-0766</identifier><identifier>DOI: 10.3109/09513590009167685</identifier><identifier>PMID: 11075290</identifier><language>eng</language><publisher>Carnforth: Informa UK Ltd</publisher><subject>3-Oxo-5-alpha-Steroid 4-Dehydrogenase - drug effects ; 5α-Reductase ; Adolescent ; Adult ; Biological and medical sciences ; Birth control ; Contraceptives, Oral - pharmacology ; Dose-Response Relationship, Drug ; Female ; Gynecology. Andrology. Obstetrics ; Hormonal contraception ; Humans ; Hyperandrogenism - prevention &amp; control ; Medical sciences ; Nandrolone - analogs &amp; derivatives ; Nandrolone - pharmacology ; Norgestrel - analogs &amp; derivatives ; Norgestrel - pharmacology ; Oral Contraceptive ; Progestin ; Progestins - pharmacology ; Receptors, Androgen - drug effects ; Skin - enzymology ; Skin - metabolism</subject><ispartof>Gynecological endocrinology, 2000, Vol.14 (4), p.223-230</ispartof><rights>2000 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2000</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c431t-7d1ca11dde84b4e667eb47e9c1b653411368412482ee822884ddb4015e9f54f73</citedby><cites>FETCH-LOGICAL-c431t-7d1ca11dde84b4e667eb47e9c1b653411368412482ee822884ddb4015e9f54f73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1516809$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11075290$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rabe, T.</creatorcontrib><creatorcontrib>Kowald, A.</creatorcontrib><creatorcontrib>Ortmann, J.</creatorcontrib><creatorcontrib>Rehberger-Schneider, S.</creatorcontrib><title>Inhibition of skin 5α-reductase by oral contraceptive progestins in vitro</title><title>Gynecological endocrinology</title><addtitle>Gynecol Endocrinol</addtitle><description>Androgenic disorders of female skin such as hirsutism, acne and alopecia are etiologically caused by androgen excess. Skin 5α-reductase activity is a major factor influencing the manifestation of endogenous androgen excess in women. Oral contraceptives have proven useful for the treatment of androgen disorders of the skin. The mechanisms of action by which oral contraceptives correct skin androgen levels may include inhibition of 5α-reductase and androgen receptor activity. We investigated the inhibitory effect of oral contraceptive progestins and ethinyl estradiol on skin 5α-reductase and their influence on androgen receptor activity and affinity, using three different in vitro assay systems. It was shown that norgestimate blocked 5α-reductase activity with an IC50 value of 10 μM, followed by levonorgestrel (IC50 52 μM), dienogest (IC50 55 μM), cyproterone acetate (IC50 87 μM) and gestodene (IC50 98 μM). To determine the full androgenic potential of the progestins, androgen receptor binding affinities and activation potentials were determined. The progestins norgestimate and dienogest in particular combined 5α-reductase inhibition with minimal androgenic potential. These data demonstrate that the progestins norgestimate and dienogest might help in the treatment of clinical hyperandrogeny in women.</description><subject>3-Oxo-5-alpha-Steroid 4-Dehydrogenase - drug effects</subject><subject>5α-Reductase</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Birth control</subject><subject>Contraceptives, Oral - pharmacology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Hormonal contraception</subject><subject>Humans</subject><subject>Hyperandrogenism - prevention &amp; control</subject><subject>Medical sciences</subject><subject>Nandrolone - analogs &amp; derivatives</subject><subject>Nandrolone - pharmacology</subject><subject>Norgestrel - analogs &amp; derivatives</subject><subject>Norgestrel - pharmacology</subject><subject>Oral Contraceptive</subject><subject>Progestin</subject><subject>Progestins - pharmacology</subject><subject>Receptors, Androgen - drug effects</subject><subject>Skin - enzymology</subject><subject>Skin - metabolism</subject><issn>0951-3590</issn><issn>1473-0766</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNp9kM9O20AQh1cVqEnTPkAvyAfEzbDj_WcLLhWiJQiJC5yt9XrcLDi7YXdNlcfqi_BMdZRUCCHlNIf5vtFvfoR8B3rKgFZntBLAREUprUAqWYpPZApcsZwqKQ_IdLPPN8CEfInxkVJgXBWfyQSAKlFUdEpu5m5hG5usd5nvsvhkXSZe_-YB28EkHTFr1pkPus-Mdylog6tkXzBbBf8bY7IuZqPxYlPwX8lhp_uI33ZzRh5-Xt1fXue3d7_mlz9uc8MZpFy1YDRA22LJG45SKmy4wspAIwXjAEyWHApeFohlUZQlb9uGUxBYdYJ3is3IyfbumOF5GEPUSxsN9r126IdYq4JTxegGhC1ogo8xYFevgl3qsK6B1psC6w8Fjs7R7vjQLLF9M3aNjcDxDtDR6L4L2hkb3zgBsqTViF1sMes6H5b6jw99Wye97n3477B9Mc7f6QvUfVoYHbB-9ENwY797nvgHEp6dNw</recordid><startdate>2000</startdate><enddate>2000</enddate><creator>Rabe, T.</creator><creator>Kowald, A.</creator><creator>Ortmann, J.</creator><creator>Rehberger-Schneider, S.</creator><general>Informa UK Ltd</general><general>Taylor &amp; Francis</general><general>Parthenon</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2000</creationdate><title>Inhibition of skin 5α-reductase by oral contraceptive progestins in vitro</title><author>Rabe, T. ; Kowald, A. ; Ortmann, J. ; Rehberger-Schneider, S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c431t-7d1ca11dde84b4e667eb47e9c1b653411368412482ee822884ddb4015e9f54f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>3-Oxo-5-alpha-Steroid 4-Dehydrogenase - drug effects</topic><topic>5α-Reductase</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Birth control</topic><topic>Contraceptives, Oral - pharmacology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Hormonal contraception</topic><topic>Humans</topic><topic>Hyperandrogenism - prevention &amp; control</topic><topic>Medical sciences</topic><topic>Nandrolone - analogs &amp; derivatives</topic><topic>Nandrolone - pharmacology</topic><topic>Norgestrel - analogs &amp; derivatives</topic><topic>Norgestrel - pharmacology</topic><topic>Oral Contraceptive</topic><topic>Progestin</topic><topic>Progestins - pharmacology</topic><topic>Receptors, Androgen - drug effects</topic><topic>Skin - enzymology</topic><topic>Skin - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rabe, T.</creatorcontrib><creatorcontrib>Kowald, A.</creatorcontrib><creatorcontrib>Ortmann, J.</creatorcontrib><creatorcontrib>Rehberger-Schneider, S.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecological endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rabe, T.</au><au>Kowald, A.</au><au>Ortmann, J.</au><au>Rehberger-Schneider, S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of skin 5α-reductase by oral contraceptive progestins in vitro</atitle><jtitle>Gynecological endocrinology</jtitle><addtitle>Gynecol Endocrinol</addtitle><date>2000</date><risdate>2000</risdate><volume>14</volume><issue>4</issue><spage>223</spage><epage>230</epage><pages>223-230</pages><issn>0951-3590</issn><eissn>1473-0766</eissn><abstract>Androgenic disorders of female skin such as hirsutism, acne and alopecia are etiologically caused by androgen excess. Skin 5α-reductase activity is a major factor influencing the manifestation of endogenous androgen excess in women. Oral contraceptives have proven useful for the treatment of androgen disorders of the skin. The mechanisms of action by which oral contraceptives correct skin androgen levels may include inhibition of 5α-reductase and androgen receptor activity. We investigated the inhibitory effect of oral contraceptive progestins and ethinyl estradiol on skin 5α-reductase and their influence on androgen receptor activity and affinity, using three different in vitro assay systems. It was shown that norgestimate blocked 5α-reductase activity with an IC50 value of 10 μM, followed by levonorgestrel (IC50 52 μM), dienogest (IC50 55 μM), cyproterone acetate (IC50 87 μM) and gestodene (IC50 98 μM). To determine the full androgenic potential of the progestins, androgen receptor binding affinities and activation potentials were determined. The progestins norgestimate and dienogest in particular combined 5α-reductase inhibition with minimal androgenic potential. These data demonstrate that the progestins norgestimate and dienogest might help in the treatment of clinical hyperandrogeny in women.</abstract><cop>Carnforth</cop><pub>Informa UK Ltd</pub><pmid>11075290</pmid><doi>10.3109/09513590009167685</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0951-3590
ispartof Gynecological endocrinology, 2000, Vol.14 (4), p.223-230
issn 0951-3590
1473-0766
language eng
recordid cdi_proquest_miscellaneous_72407307
source Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
subjects 3-Oxo-5-alpha-Steroid 4-Dehydrogenase - drug effects
5α-Reductase
Adolescent
Adult
Biological and medical sciences
Birth control
Contraceptives, Oral - pharmacology
Dose-Response Relationship, Drug
Female
Gynecology. Andrology. Obstetrics
Hormonal contraception
Humans
Hyperandrogenism - prevention & control
Medical sciences
Nandrolone - analogs & derivatives
Nandrolone - pharmacology
Norgestrel - analogs & derivatives
Norgestrel - pharmacology
Oral Contraceptive
Progestin
Progestins - pharmacology
Receptors, Androgen - drug effects
Skin - enzymology
Skin - metabolism
title Inhibition of skin 5α-reductase by oral contraceptive progestins in vitro
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T09%3A09%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20skin%205%CE%B1-reductase%20by%20oral%20contraceptive%20progestins%20in%20vitro&rft.jtitle=Gynecological%20endocrinology&rft.au=Rabe,%20T.&rft.date=2000&rft.volume=14&rft.issue=4&rft.spage=223&rft.epage=230&rft.pages=223-230&rft.issn=0951-3590&rft.eissn=1473-0766&rft_id=info:doi/10.3109/09513590009167685&rft_dat=%3Cproquest_cross%3E72407307%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c431t-7d1ca11dde84b4e667eb47e9c1b653411368412482ee822884ddb4015e9f54f73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=72407307&rft_id=info:pmid/11075290&rfr_iscdi=true